Regulatory Considerations of Biosimilars in Cancer

In the fast-evolving field of cancer treatment, the introduction of biosimilars has brought about significant changes in the available therapeutic options. Biosimilars, which are identical to the original biologic drugs, offer a promising opportunity to increase patient access to effective and more affordable cancer treatments. However, the rules and regulations governing biosimilars in oncology play a crucial role in ensuring their safety, effectiveness, and successful integration into clinical practice. Effectively managing the existing regulations is essential to establish a robust environment for innovation, prioritize patient welfare, and ensure fair access to quality cancer care. Biosimilar regulations are designed to guarantee that medicines similar to existing ones are both safe and effective. A well-established regulatory environment builds confidence in the safety and efficacy of biosimilars, forming the basis for advancements in cancer treatment. These regulations also help maintain quality standards for affordable alternatives to biological drugs. This chapter emphasizes the regulatory considerations linked with biosimilars in cancer treatment, shedding light on the complexities and implications for healthcare professionals, regulatory authorities, and, most importantly, patients.